Results 31 to 40 of about 2,872,365 (306)

Mortality among individuals prescribed opioid-agonist therapy in Scotland, UK, 2011-20: a national retrospective cohort study.

Lancet Public Health, 2023
BACKGROUND Drug-related death (DRD) rate in Scotland, UK, has increased rapidly to one of the highest in the world. Our aim was to examine the extent to which opioid-agonist therapy (OAT) in Scotland is protective against drug-related mortality and how ...
Andrew McAuley, Rosalyn Fraser, M. Glancy, A. Yeung, H. Jones, P. Vickerman, Hannah Fraser, Lara I Allen, S. McDonald, J. Stone, D. Liddell, L. Barnsdale, Saket Priyadarshi, Andreas Markoulidakis, M. Hickman, S. Hutchinson   +15 more
semanticscholar   +1 more source

Opioid Agonist Therapy Adherence Trajectories Among Commercially and Publicly Insured People Living With Hepatitis C in the United States. [PDF]

Epidemiology
BACKGROUND: Hepatitis C virus (HCV) infection is a public health concern, with people living with opioid use disorder having a higher risk of infection. Despite the cooccurrence of HCV and opioid use disorder, little is known about the treatment patterns
Psaras C, Psaras C, Arah OA, Chew KW, Lee SJ, Javanbakht M, Nianogo RA, Seamans MJ.   +7 more
europepmc   +2 more sources

COMPREHENSIVE NEEDLE AND SYRINGE PROGRAM AND OPIOID AGONIST THERAPY REDUCE HIV AND HEPATITIS C VIRUS ACQUISITION AMONG PEOPLE WHO INJECT DRUGS IN DIFFERENT SETTINGS: A POOLED ANALYSIS OF EMULATED TRIALS

Addiction, 2023
Background and Aims Although the Netherlands, Canada and Australia were early adopters of harm reduction for people who inject drugs (PWID), their respective HIV and hepatitis C (HCV) epidemics differ.
D. V. van Santen, S. Lodi, P. Dietze, W. van den Boom, K. Hayashi, Hui-Ru Dong, Z. Cui, L. Maher, M. Hickman, A. Boyd, M. Prins   +10 more
semanticscholar   +1 more source

Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial

Frontiers in Psychiatry, 2022
The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest outcomes among those in addiction treatment, and current ...
Christopher S. Stauffer, Christopher S. Stauffer, Christopher S. Stauffer, Salem Samson, Alex Hickok, Alex Hickok, William F. Hoffman, William F. Hoffman, Steven L. Batki   +8 more
doaj   +1 more source

Opioid agonist therapy for opioid use disorder in primary versus specialty care. [PDF]

Cochrane Database Syst Rev
Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small.
Perry D, Kirkwood JE, Doroshuk ML, Kelmer M, Korownyk CS, Ton J, Garrison SR.   +6 more
europepmc   +3 more sources

Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study

Substance Abuse Treatment, Prevention, and Policy, 2023
Background Rural and smaller urban settings in Canada are disproportionately impacted by the overdose crisis, highlighting the need for novel public health interventions within these jurisdictions.
Geoff Bardwell, J. Bowles, Manal Mansoor, D. Werb, T. Kerr   +4 more
semanticscholar   +1 more source

Effect of fruit smoothie supplementation on psychological distress among people with substance use disorders receiving opioid agonist therapy: protocol for a randomised controlled trial (FruktBAR)

BMC Nutrition, 2022
Background People with substance use disorders generally have unhealthy diets, including limited intake of fruit and vegetables. Evidence shows substantial health benefits from increasing fruit and vegetable consumption on various indicators and possibly
Lars T. Fadnes, Einar Furulund, Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Jørn Henrik Vold, Maria Olsvold, Marianne Cook Pierron, Siv-Elin Leirvåg Carlsen, Rune Blomhoff, Torgeir Gilje Lid, for the ATLAS4LAR Study Group   +10 more
doaj   +1 more source

THC Modulates Pain Sensitivity Among Persons Receiving Opioid Agonist Therapy for Opioid Use Disorder: A Within-Subject, Randomized, Placebo-Controlled Laboratory Study

Addiction Biology, 2023
The opioid and cannabinoid receptor systems are inextricably linked—overlapping at the anatomical, functional and behavioural levels. Preclinical studies have reported that cannabinoid and opioid agonists produce synergistic antinociceptive effects ...
J. D. de Aquino, Julia V. Meyerovich, Catherine Z. Xie, M. Ranganathan, Peggy Compton, Brian Pittman, Michael Rogan, M. Sofuoglu   +7 more
semanticscholar   +1 more source

Personal viewpoint on opioid agonist therapy and transplantation [PDF]

American Journal of Transplantation, 2018
Opioid use disorder (OUD) is an increasing public health problem. Transplant centers worldwide are being confronted with increasing numbers of patients with opioid use disorder and end stage organ disease. Opioid agonist therapy (OAT; ie, methadone, buprenorphine, and buprenorphine/naloxone) is a scientifically proven, effective, physician-prescribed ...
Ana, Ivkovic, Sarah, Wakeman
openaire   +2 more sources

First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada

Drug and Alcohol Dependence Reports, 2023
Background: Among people who inject drugs, frequent injecting and experiencing withdrawal are associated with facilitating others’ first injections. As these factors may reflect an underlying substance use disorder, we investigated whether first-line ...
Zachary Bouck, Andrea C. Tricco, Laura C. Rosella, Hailey R. Banack, Matthew P. Fox, Robert W. Platt, M-J Milloy, Kora DeBeck, Kanna Hayashi, Dan Werb   +9 more
doaj   +1 more source